CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 297 enrolled / 297 target
Drug / intervention
mCRM Therapy Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04798768
NCT04798768N/AActiveUpdate Overdue (5.0/mo)Completion was 25mo ago

Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing

Boston Scientific Corporation·interventional·Posted Mar 15, 2021·Updated Jun 26, 2026

In Brief

A clinical study evaluating mCRM Therapy System for Tachycardia, Ventricular and Arrhythmia, Ventricular. Active but no longer recruiting, targeting 297 participants across 38 sites in 9 countries.

Signals

Enrollment appears stalled

Detailed Summary

The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Canada, Czechia, France, Italy, Netherlands, Spain, United Kingdom, United States
Collaborators--

Timeline

N/AActive
20212022202320242025202620272028202920302031
First PostedMar 15, 2021
Enrollment StartJul 20, 2021
Primary CompletionMay 6, 2024
Study CompletionDec 31, 2030
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.3 years ago

Arms & Interventions

MODULAR ATP Study Participantsexperimental

All subjects that signed the informed consent were included. Patients consented to receive the mCRM Therapy System which consists of the EMPOWER Leadless Pacemaker and an EMBLEM S-ICD upgraded with investigational firmware.

Device: mCRM Therapy System

Interventions

mCRM Therapy Systemdevice

Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.